Overview
HIMS market data
Price History
HIMS price chart · 1M
- O
- 27.60
- H
- 27.86
- L
- 27.40
- C
- 27.71
- Vol
- 178,584.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $27.60
- Previous Close
- $27.84
- Day High
- $27.86
- Day Low
- $27.40
- 52 Week High
- $39.04
- 52 Week Low
- $21.53
- 7 Day Return
- -3.87%
- 30 Day Return
- -12.48%
- 90 Day Return
- +1.95%
- 1 Year Return
- -4.92%
- Daily Notional Volume
- $4.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 50.57 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.50 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.74 – $65.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.5B · P/B 13.66 · P/S 2.52.
Company News
10 captured
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026Globenewswire Inc ·
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSSGlobenewswire Inc ·
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite LossZacks Investment Research ·